



NATCO PHARMA LIMITED

Statement of stand-alone Financial Results for the quarter and half year ended 30th September 2015

Rs. in lakhs

PART I : STATEMENT OF STAND-ALONE FINANCIAL RESULTS						
PARTICULARS	THREE MONTHS ENDED (REVIEWED/UN-AUDITED)			YEAR-TO-DATE FIGURES FOR THE HALF YEAR ENDED ON (REVIEWED/UN-AUDITED)		YEAR ENDED (AUDITED)
	30 September 2015	30 June 2015	30 September 2014	30 September 2015	30 September 2014	31 March 2015
01. Gross Sales/Income from Operations	20,435	19,699	18,677	40,134	35,627	69,164
Less: Excise Duty	809	530	215	1,339	557	1,143
Less: Sales Tax	635	552	351	1,187	759	1,571
Net Sales/Income from Operations	18,991	18,617	18,111	37,608	34,311	66,450
02. Other Operating Income	1,213	788	1,017	2,001	2,965	5,107
03. TOTAL INCOME FROM OPERATIONS	20,204	19,405	19,128	39,609	37,276	71,557
04. EXPENDITURE						
a) Cost of materials consumed	6,376	6,181	3,820	12,557	7,712	17,858
b) Purchases of stock-in-trade	-	37	-	37	-	88
c) Changes in inventories of finished goods, work-in progress and stock-in-trade	(1,838)	(1,025)	725	(2,863)	1,202	(876)
d) Employee benefits expense	3,551	3,464	2,909	7,015	5,624	11,619
e) Depreciation and amortization expense	1,124	1,120	1,023	2,244	2,042	4,246
f) Other Expenses	6,037	4,693	5,586	10,730	10,594	20,010
TOTAL EXPENSES	15,250	14,470	14,063	29,720	27,174	52,945
05. Profit/(Loss) from Operations before other income, finance costs and exceptional items	4,954	4,935	5,065	9,889	10,102	18,612
06. Other Income	308	283	300	591	388	1,355
07. Profit/(Loss) from ordinary activities before finance Cost and exceptional items	5,262	5,218	5,365	10,480	10,490	19,967
08. Finance costs	754	777	699	1,531	1,335	3,013
09. Profit/(Loss) from ordinary activities after finance Costs but before exceptional items	4,508	4,441	4,666	8,949	9,155	16,954
10. Exceptional Item	-	-	-	-	-	1,513
11. Profit/(Loss) from ordinary activities before tax	4,508	4,441	4,666	8,949	9,155	15,441
12. Current Tax expense	962	948	991	1,910	1,932	3,252
13. Deferred Tax expense /(reversal)	86	86	195	172	102	(3,103)
14. Net Profit/(Loss) from ordinary activities after tax	3,460	3,407	3,480	6,867	7,121	15,292
15. Extraordinary items (net of tax expenses)	-	-	-	-	-	-
16. Net Profit/(Loss) for the period	3,460	3,407	3,480	6,867	7,121	15,292
17. Paid-up Equity Share Capital (each share of Rs.10/-face value)	3,483	3,323	3,307	3,483	3,307	3,323
18. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year	-	-	-	-	-	84,576
19. Earnings per share						
Basic and diluted EPS before and after extraordinary item (Rs.) – non-annualized	10.35	10.25	10.52	20.60	21.53	46.17
	10.35	10.25	10.52	20.60	21.53	46.17
PART II : SELECT INFORMATION						
20. Public Share holding :						
a) Number of Shares	1,69,68,985	1,53,68,985	1,53,73,943	1,69,68,985	15373943	1,53,73,985
b) Percentage of Share holding	48.71	46.24	46.48	48.71	46.48	46.26
21. Promoters and Promoter Group Shareholding						
a) Pledged/Encumbered – No.of shares	-	-	-	-	-	-
b) Non-encumbered-No.of shares	1,78,65,864	1,78,65,864	1,76,99,131	1,78,65,864	1,76,99,131	1,78,60,864
Percentage (as a % of the total share holding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
Percentage (as a % of the total share capital of the company)	51.29	53.76	53.52	51.29	53.52	53.74

Dated at Hyderabad, this, the 13th day of November, 2015.
for and on behalf of the Board of Directors,
NATCO Pharma Limited

V. C. Nannapaneni
Chairman & Managing Director

Pending as on 01-07-2015	-
Received during the quarter	124
Resolved during the quarter	124
Pending as on 30-09-2015	-

Regd. Office: NATCO House, Road # 2, Banjara Hills, Hyderabad : 500 034



NATCO PHARMA LIMITED

Report of segment wise revenue, Results and Capital Employed (Un-audited) under Clause 41 of the Listing Agreement, for the quarter and half year ended on 30th September, 2015

Rs. In lakhs

PARTICULARS	THREE MONTHS ENDED (UN-REVIEWED/UN-AUDITED)			HALF YEAR ENDED (UN-REVIEWED/UN-AUDITED)		PREVIOUS ACCOUNTING YEAR ENDED (UN-AUDITED)
	30-Sep-15	30-Jun-15	30-Sep-14	30-Sep-15	30-Sep-14	
01. Segment Revenue(Net)						
a) Bulk Chemicals	5,198	5,580	7,431	10,778	15,958	29,468
b) Formulations	15,910	14,146	11,882	30,056	20,848	42,524
c) Job Work	127	221	206	348	436	830
d) Unallocated	31	326	240	357	1,210	2,502
Total	21,266	20,273	19,759	41,539	38,452	75,324
Less: Inter-Segment Revenue	1,062	868	631	1,930	1,176	3,767
Net Sales/Income from Operations	20,204	19,405	19,128	39,609	37,276	71,557
02. Segment Results: Profit(+)/Loss(-) before tax and interest						
a) Bulk Chemicals	495	1,134	761	1,629	4,718	8,043
b) Formulations	6,781	5,712	6,579	12,493	9,647	17,784
c) Job Work	108	190	178	298	361	684
d) Unallocated	77	243	41	320	94	1,354
Total	7,461	7,279	7,559	14,740	14,820	27,865
Less: a) Interest	754	777	699	1,531	1,335	3,013
b) Other unallocable expenditure	2,507	2,344	2,494	4,851	4,718	10,766
c) Unallocable Income	(308)	(283)	(300)	(591)	(388)	(1,355)
Total Profit Before Tax	4,508	4,441	4,666	8,949	9,155	15,441
03. Capital Employed (Segment Assets- Segment Liabilities)						
a) Bulk Chemicals	47,598	46,963	46,920	47,598	46,920	44,091
b) Formulations	47,164	45,123	40,074	47,164	40,074	44,740
c) Job Work	41	101	173	41	173	227
d) Unallocated (Others)	33,408	(881)	(7,170)	33,408	(7,170)	(1,159)
Total	1,28,211	91,306	79,997	1,28,211	79,997	87,899

The above un-audited financial results were reviewed by the Audit Committee, Statutory Auditors and approved by the Board of Directors at a meeting held at Hyderabad, on Friday, the 13th November, 2015. Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary.

The Company has allotted 1,600,000 equity shares of Rs.10 each at a premium of Rs.2,120.55 per equity share on 18 September 2015 pursuant to a Qualified Institutions Placement under Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 (as amended). Share issue expenses amounting to Rs.642 lakhs have been adjusted against the Securities Premium Account in terms of the provisions of Section 52 of the Companies Act, 2013 instead of charging to Statement of Profit and Loss account as done earlier.

As at 30 September 2015, Short term loans and advances includes term deposits with financial institutions amounting to ₹4,000 lakhs.

Dated at Hyderabad, this, the 13th day of November, 2015.

for and on behalf of the Board of Directors,

NATCO Pharma Limited

V. C. Nannapaneni
Chairman & Managing Director

Regd. Office: NATCO House, Road # 2, Banjara Hills, Hyderabad : 500 034



NATCO PHARMA LIMITED
STATEMENT OF STAND-ALONE ASSETS AND LIABILITIES

Rs. In lakhs

Particulars	As at 30-Sep-2015 (Reviewed/Unaudited)	As at 31-Mar-2015 (Audited)
Equity & Liabilities		
Shareholders' Funds		
a) Share Capital	3,483	3,323
b) Reserves & Surplus	1,24,728	84,576
Sub-total: Shareholders' Funds	1,28,211	87,899
Non-current liabilities		
a) Long term borrowings	342	9,628
b) Deferred tax liabilities(net)	1,301	1,129
c) Other long-term liabilities	77	77
d) Long term provisions	1,117	919
Sub-total: Non-current Liabilities	2,837	11,753
Current Liabilities		
a) Short term borrowings	10,821	16,854
b) Trade payables	15,890	11,534
c) Other current liabilities	8,692	11,332
d) Short-term provisions	111	111
Sub-total: Current Liabilities	35,514	39,831
TOTAL- EQUITY AND LIABILITIES	1,66,562	1,39,483
Assets		
Non-Current Assets		
a) Fixed Assets		
Tangible Assets	58,112	56,802
Intangible Assets	457	471
b) Capital Work-in-progress	12,932	10,077
c) Non- Current Investments	14,295	13,115
d) Long term loans and advances	15,999	14,247
e) Other non-current assets	367	352
Sub-total: Non-Current Assets	1,02,162	95,064
Current Assets		
a) Current Investments	2,012	12
b) Inventories	24,938	19,835
c) Trade receivables	19,843	18,896
d) Cash and Cash Equivalents	7,485	719
e) Short term loans and advances	9,661	4,766
f) Other Current Assets	461	191
Sub-total: Current Assets	64,400	44,419
TOTAL- ASSETS	1,66,562	1,39,483